Company Info
Industry | Pharmaceuticals: Major |
---|---|
Sector | Health Technology |
Employees | 928 |
CEO | Dr. Vladimir Coric |
Address | 215 Church Street , New Haven, CT 06510-1803 |
---|---|
Phone | 1.203.404.0410 |
Website | www.biohavenpharma.com |
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
Statement Summary
as of 4:00 ET PM 05/19/2022Total Assets (MRQ) | 1.4 B |
---|---|
Total Liabilities (MRQ) | 1.8 B |
Shareholders’ Equity (MRQ) | -466.4 M |
Total Revenue (Annual) | 318.9 M |
Net Income (Annual) | -116.4 M |
Earnings And Estimates
as of 4:00 ET PM 05/19/2022
Current Qtr EPS Estimate | -2.58 |
---|---|
Current FY EPS Estimate | -10.76 |
Long Term EPS Growth Estimate | n/a |
Next Expected Earnings Date | 8/15/2022 |
BHVN vs S&P 500
as of 05/19/2022Relative To S&P 500 |
BHVN | |
---|---|---|
4 Weeks | n/a | n/a |
12 Weeks | n/a | n/a |
YTD | n/a | n/a |
Earnings Surprises
as of 4:00 ET PM 05/19/2022Fiscal Quarter | Estimate | Actual | Surprise |
---|---|---|---|
03/2022 | -2.55 | -2.97 | +16.47% |
12/2021 | -1.94 | -3.01 | +54.99% |
09/2021 | -2.37 | -2.63 | +11.15% |
06/2021 | -2.73 | -3.23 | +18.40% |
03/2021 | -2.85 | -4.21 | +47.84% |
12/2020 | -2.90 | -3.62 | +25.00% |
09/2020 | -2.84 | -3.27 | +15.26% |
06/2020 | -2.69 | -3.08 | +14.36% |
Financial Strength
as of 4:00 ET PM 05/19/2022Pre-Tax Margin | -29.04 |
---|---|
Net Margin | 93.96 |
Operating Margin | -16.88 |
Return On Equity | 0.00 |
Return On Assets | -58.78 |
Inventory Turnover (TTM) | 1.41 |
Sales Growth (MRQ) | n/a |
Ratios
as of 4:00 PM ET 05/19/2022Price/Earnings (TTM) | n/a |
---|---|
Price/Book (MRQ) | 0.00 |
Price/Cash Flow (TTM) | 0.00 |
Book Value (MRQ) | -6.55 |
Quick Ratio (MRQ) | 1.87 |
Current Ratio (MRQ) | 2.03 |
Total Debt/Equity (MRQ) | 0.00 |
Short Interest
as of 4:00 PM ET 05/20/2022% Short - 7.90% | |
% Remaining Float - 92.10% |
Current | Last Month | |
---|---|---|
Short Interest Date | 04/29/2022 | 04/14/2022 |
Short Interest Shares | 4,928,281 | 4,710,102 |
Short Interest Ratio | 5.4 | 6.7 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
---|---|---|
Balance Sheet
M Y | ||||
---|---|---|---|---|
ASSETS | ||||
Cash And Equivalents | 0,0.00 | |||
Receivables | 0,0.00 | |||
Inventories | 0,0.00 | |||
Other Current Assets | 0,0.00 | |||
Total Current Assets | 0,0.00 | |||
Property, Plant & Equipment, Gross | 0,0.00 | |||
Accumulated Depreciation & Depletion | 0,0.00 | |||
Property, Plant & Equipment, Net | 0,0.00 | |||
Intangibles | 0,0.00 | |||
Other Non-Current Assets | 0,0.00 | |||
Total Non-Current Assets | 0,0.00 | |||
TOTAL ASSETS | 0,0.00 | |||
Liabilities & Shareholder Equity | ||||
Accounts Payable | 0,0.00 | |||
Short Term Debt | 0,0.00 | |||
Total Current Liabilities | 0,0.00 | |||
Long Term Debt | 0,0.00 | |||
Deferred Income Taxes | 0,0.00 | |||
Other Non-Current Liabilities | 0,0.00 | |||
Minority Interest | 0,0.00 | |||
Total Non-Current Liabilities | 0,0.00 | |||
Preferred Stock Equity | 0,0.00 | |||
Common Stock Equity | 0,0.00 | |||
Common Par | 0,0.00 | |||
Additional Paid In Capital | 0,0.00 | |||
Cumulative Translation Adjustment | 0,0.00 | |||
Retained Earnings | 0,0.00 | |||
Treasury Stock | 0,0.00 | |||
Other Equity Adjustments | 0,0.00 | |||
Total Capitalization | 0,0.00 | |||
TOTAL EQUITY | 0,0.00 | |||
TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
Total Common Shares Outstanding | 0,0.00 | |||
Preferred Shares | 0,0.00 | |||
Treasury Shares | 0,0.00 | |||
Basic Weighted Shares Outstanding | 0,0.00 | |||
Diluted Weighted Shares Outstanding | 0,0.00 | |||
Number Of Employees | 0,0.00 | |||
Number Of Part-Time Employees | 0,0.00 |
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
---|---|---|
Income Statement
M Y | |
---|---|
Sales | 0,0.00 |
Cost Of Sales | 0,0.00 |
Gross Operating Profit | 0,0.00 |
Selling, General, And Administrative Expenses | 0,0.00 |
Research & Development | 0,0.00 |
Operating Income Before D & A (EBITDA) | 0,0.00 |
Depreciation & Amortization | 0,0.00 |
Interest Income | 0,0.00 |
Other Income - Net | 0,0.00 |
Special Income / Charges | 0,0.00 |
Total Income Before Interest Expenses (EBIT) | 0,0.00 |
Interest Expense | 0,0.00 |
Pre-Tax Income | 0,0.00 |
Income Taxes | 0,0.00 |
Minority Interest | 0,0.00 |
Net Income From Continuing Operations | 0,0.00 |
Net Income From Discontinued Operations | 0,0.00 |
Net Income From Total Operations | 0,0.00 |
Extraordinary Income/Losses | 0,0.00 |
Income From Cum. Effect Of Acct. Change | 0,0.00 |
Income From Tax Loss Carryforward | 0,0.00 |
Other Gains / Losses | 0,0.00 |
Total Net Income | 0,0.00 |
Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
Preferred Dividends | 0,0.00 |
Net Income Available To Common | 0,0.00 |
Basic EPS From Continuing Ops. | 0,0.00 |
Basic EPS From Discontinued Ops. | 0,0.00 |
Basic EPS From Total Operations | 0,0.00 |
Basic EPS From Extraordinary Inc. | 0,0.00 |
Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
Basic EPS From Other Gains (Losses) | 0,0.00 |
Basic EPS, Total | 0,0.00 |
Basic Normalized Net Income/Share | 0,0.00 |
EPS From Continuing Ops. | 0,0.00 |
EPS From Discontinued Ops | 0,0.00 |
EPS From Total Ops. | 0,0.00 |
EPS From Extraord. Inc. | 0,0.00 |
EPS From Cum Effect of Accounting Change | 0,0.00 |
EPS From Tax Loss Carfd. | 0,0.00 |
EPS From Other Gains (L) | 0,0.00 |
EPS, Total | 0,0.00 |
Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
---|---|---|
Cash Flow Statement
M Y | ||||
---|---|---|---|---|
Cash Flow From Operating Activities | ||||
Net Income (Loss) | 0,0.00 | |||
Operating Gains/Losses | 0,0.00 | |||
Gross Operating Profit | 0,0.00 | |||
(Increase) Decrease In Receivables | 0,0.00 | |||
(Increase) Decrease In Inventories | 0,0.00 | |||
(Increase) Decrease In Other Current Assets | 0,0.00 | |||
(Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
(Increase) Decrease In Other Working Capital | 0,0.00 | |||
Other Non-Cash Items | 0,0.00 | |||
Net Cash From Continuing Operations | 0,0.00 | |||
Net Cash From Discontinued Operations | 0,0.00 | |||
Cash Provided By Investing Activities | ||||
Net Cash From Total Operating Activities | 0,0.00 | |||
Sale Of Property, Plant & Equipment | 0,0.00 | |||
Cash Used For Investing Activities | ||||
Sale Of Short-Term Investments | 0,0.00 | |||
Purchases Of Property, Plant & Equipment | 0,0.00 | |||
Acquisitions | 0,0.00 | |||
Purchases Of Short-Term Investments | 0,0.00 | |||
Other Cash From Investing Activities | 0,0.00 | |||
Cash Provided by Financing Activities | ||||
Net Cash From Investing Activities | 0,0.00 | |||
Issuance Of Debt | 0,0.00 | |||
Cash Used For Financing Activities | ||||
Issuance Of Capital Stock | 0,0.00 | |||
Repayment Of Long-Term Debt | 0,0.00 | |||
Repurchase Of Capital Stock | 0,0.00 | |||
Payment Of Cash Dividends | 0,0.00 | |||
Other Financing Charges, Net | 0,0.00 | |||
Net Cash From Financing Activities | 0,0.00 | |||
Effect Of Exchange Rate Changes | 0,0.00 | |||
Net Change In Cash & Cash Equivalents | 0,0.00 |
Earnings Estimates
as of 4:00 ET PM 05/19/2022Current Qtr (06/2022) |
Next Qtr (09/2022) |
|
---|---|---|
Consensus Estimate | $-2.58 | $-2.26 |
# of Estimates | 7 | 7 |
High Estimate | $-1.81 | $-1.52 |
Low Estimate | $-4.04 | $-3.34 |
Year Ago EPS | $-3.23 | $-2.63 |
Year Over Year Growth Estimate | -20.15% | -13.94% |
Current Yr (12/2022) |
Next Yr (12/2023) |
|
---|---|---|
Consensus Estimate | $-10.76 | $-5.69 |
# of Estimates | 8 | 8 |
High Estimate | $-7.72 | $-1.16 |
Low Estimate | $-17.08 | $-10.62 |
Year Ago EPS | $-13.09 | $-10.76 |
Year Over Year Growth Estimate | -17.83% | -47.14% |
Current Qtr (06/2022) |
Next Qtr (09/2022) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Consensus Estimate | $-2.58 | $-2.26 | $-10.76 | $-5.69 |
# of Estimates | 7 | 7 | 8 | 8 |
High Estimate | $-1.81 | $-1.52 | $-7.72 | $-1.16 |
Low Estimate | $-4.04 | $-3.34 | $-17.08 | $-10.62 |
Year Ago EPS | $-3.23 | $-2.63 | $-13.09 | $-10.76 |
Year Over Year Growth Estimate | -20.15% | -13.94% | -17.83% | -47.14% |
Insider Information Summary
as of 04/30/2022% Insiders - 12.60% | |
% Remaining Total Shares - 87.40% |
Current | 1 Month | |
---|---|---|
Net Insider Transaction | 0.00 | 38.86 K |
Shares Bought | 0.00 | 80.98 K |
Shares Sold | 0.00 | 42.12 K |
Insider Activity
Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
---|---|---|---|---|---|---|---|---|---|---|
Latest News
Cramer's Mad Money Recap 11/10: Rivian, Tesla, Amazon
Nov 10, 2021 7:10 PM EST
Cramer's Mad Money Recap: J&J, Netflix, Nvidia, Tesla
Oct 15, 2021 7:22 PM EDT
Cramer's Mad Money Recap 9/9/21: Affirm, Amazon
Sep 9, 2021 7:06 PM EDT